162 related articles for article (PubMed ID: 26710712)
1. Acalabrutinib for relapsed chronic lymphocytic leukaemia.
Burki TK
Lancet Oncol; 2016 Feb; 17(2):e48. PubMed ID: 26710712
[No Abstract] [Full Text] [Related]
2. Acalabrutinib and its use in treatment of chronic lymphocytic leukemia.
Khan Y; O'Brien S
Future Oncol; 2019 Feb; 15(6):579-589. PubMed ID: 30381956
[TBL] [Abstract][Full Text] [Related]
3. Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results.
Byrd JC; Wierda WG; Schuh A; Devereux S; Chaves JM; Brown JR; Hillmen P; Martin P; Awan FT; Stephens DM; Ghia P; Barrientos J; Pagel JM; Woyach JA; Burke K; Covey T; Gulrajani M; Hamdy A; Izumi R; Frigault MM; Patel P; Rothbaum W; Wang MH; O'Brien S; Furman RR
Blood; 2020 Apr; 135(15):1204-1213. PubMed ID: 31876911
[TBL] [Abstract][Full Text] [Related]
4. Acalabrutinib: First Global Approval.
Markham A; Dhillon S
Drugs; 2018 Jan; 78(1):139-145. PubMed ID: 29209955
[TBL] [Abstract][Full Text] [Related]
5. Images in Vascular Medicine. Rumpel-Leede phenomenon in a patient with chronic lymphocytic leukemia treated with acalabrutinib.
Bossory Goike L; Dean S
Vasc Med; 2020 Jun; 25(3):281-282. PubMed ID: 32146868
[No Abstract] [Full Text] [Related]
6. Clinical and biological implications of target occupancy in CLL treated with the BTK inhibitor acalabrutinib.
Sun C; Nierman P; Kendall EK; Cheung J; Gulrajani M; Herman SEM; Pleyer C; Ahn IE; Stetler-Stevenson M; Yuan CM; Maric I; Gaglione EM; Harris HM; Pittaluga S; Wang MH; Patel P; Farooqui MZH; Izumi R; Hamdy A; Covey T; Wiestner A
Blood; 2020 Jul; 136(1):93-105. PubMed ID: 32202637
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib.
Jain P; Kanagal-Shamanna R; Zhang S; Ok CY; Navsaria L; Nastoupil L; Lee HJ; Tang G; Yin CC; Badillo M; Nair R; Li S; Patel KM; Flowers C; Vega F; Wang L; Wang ML
Am J Hematol; 2021 May; 96(5):E137-E140. PubMed ID: 33491779
[No Abstract] [Full Text] [Related]
8. Pharmacodynamic Analysis of BTK Inhibition in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib.
Alsadhan A; Cheung J; Gulrajani M; Gaglione EM; Nierman P; Hamdy A; Izumi R; Bibikova E; Patel P; Sun C; Covey T; Herman SEM; Wiestner A
Clin Cancer Res; 2020 Jun; 26(12):2800-2809. PubMed ID: 32054731
[TBL] [Abstract][Full Text] [Related]
9. Acalabrutinib in chronic lymphocytic leukemia.
Martino EA; Bruzzese A; Vigna E; Iaccino E; Mendicino F; Lucia E; Olivito V; Filippelli G; Neri A; Morabito F; Gentile M
Expert Opin Pharmacother; 2023 Apr; 24(5):545-549. PubMed ID: 36943916
[No Abstract] [Full Text] [Related]
10. The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable
Golay J; Ubiali G; Introna M
Haematologica; 2017 Oct; 102(10):e400-e403. PubMed ID: 28642301
[No Abstract] [Full Text] [Related]
11. Pseudo-Richter Transformation of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma After Temporary Acalabrutinib Interruption.
Shi M; Yuan J
Mayo Clin Proc; 2024 Jun; 99(6):867-868. PubMed ID: 38691072
[No Abstract] [Full Text] [Related]
12. Acalabrutinib: Nursing Considerations for Use in Patients With Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma.
Nierman P
Clin J Oncol Nurs; 2021 Dec; 25(6):687-696. PubMed ID: 34800101
[TBL] [Abstract][Full Text] [Related]
13. Effective treatment of pleural effusion in chronic lymphocytic leukemia with acalabrutinib: a case report.
Kurosawa S; Yokota T; Takada Y; Okubo S; Masuda M; Nakayama H; Sakurai A; Ito C; Aisa Y; Nakazato T
Ann Hematol; 2024 May; 103(5):1779-1781. PubMed ID: 38512464
[No Abstract] [Full Text] [Related]
14. A matching-adjusted indirect comparison of acalabrutinib versus zanubrutinib in relapsed or refractory chronic lymphocytic leukemia.
Kittai AS; Skarbnik A; Miranda M; Yong ASM; Roos J; Hettle R; Palazuelos-Munoz S; Shetty V; Ghia P
Am J Hematol; 2023 Dec; 98(12):E387-E390. PubMed ID: 37811799
[No Abstract] [Full Text] [Related]
15. 2019 ASH Annual Meeting.
Yaqub F
Lancet Haematol; 2020 Jan; 7(1):e12-e13. PubMed ID: 31859224
[No Abstract] [Full Text] [Related]
16. Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies.
Furman RR; Byrd JC; Owen RG; O'Brien SM; Brown JR; Hillmen P; Stephens DM; Chernyukhin N; Lezhava T; Hamdy AM; Izumi R; Patel P; Baek M; Christian B; Dyer MJS; Streetly MJ; Sun C; Rule S; Wang M; Ghia P; Jurczak W; Pagel JM; Sharman JP
Leukemia; 2021 Nov; 35(11):3201-3211. PubMed ID: 33907299
[TBL] [Abstract][Full Text] [Related]
17. Comment on: "Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients".
Visentin A; Trentin L
Haematologica; 2022 Jun; 107(6):1489-1490. PubMed ID: 34788988
[No Abstract] [Full Text] [Related]
18. Response to Comment on: "Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients".
Brown JR
Haematologica; 2022 Jun; 107(6):1491-1492. PubMed ID: 34788990
[No Abstract] [Full Text] [Related]
19. Tolerability of acalabrutinib in patients with CLL: experience of a tertiary cancer care center.
McGhie A; Lee J; Ferrajoli A; DiPippo AJ
Leuk Lymphoma; 2023 May; 64(5):1050-1053. PubMed ID: 36891585
[No Abstract] [Full Text] [Related]
20. Recent data for acalabrutinib in chronic lymphocytic leukemia.
Ghia P
Clin Adv Hematol Oncol; 2022 Jan; 20(1):27-29. PubMed ID: 35060959
[No Abstract] [Full Text] [Related]
[Next] [New Search]
